USA flag logo/image

An Official Website of the United States Government

Search

Note: The awards database is continually being updated to reflect accurate data as agencies upload their award information

Download to spreadsheetPrint
Displaying 1 – 25 of 147 Awards
Company: AURITEC PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … as these are currently the only drugs to have demonstrated efficacy in clinical studies of HIV transmission. Maraviroc the only other antiretroviral to show protection against SHIV transmission in macaques. Funded in part by R21, R33,and SBIR grants from the NIAID, we have… more
Company: BOLDER BIOTECHNOLOGY, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is… more
Company: PROFECTUS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … rhFLSC provided significant protection against rectal challenge with multiple, low doses of R5 tropic, and heterologous SHIV162P3. These observations propelled FLSC into preclinical development and evaluation in a phase 1 clinical trial (supported by BMGF, MHRP, NIAID).… more
Company: SANARIA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … manufacture of PfSPZ for infection of volunteers to testvaccines and drugs (PfSPZ Challenge) and for vaccination with PfSPZ Challenge under chloroquine protection (PfSPZ-CVac). In late November 2012 our collaborators at the Vaccine Research Center, NIAID, NIH,… more
Company: TSRL, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … context, as are the possible emergence of new pathogens and the potential for development of drug resistance in existing strains. The development of new compounds effective against a broad spectrum of known and emergent viral pathogens is thus a high priority for NIAID.… more
Company: VIROGENICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): A major goal expressed by NIAID and other agencies charged with development of the U.S. biodefense research strategy is a broad spectrum activity that mitigates catastrophic biothreats across a wide spectrum of agents.Such therapeutic… more
Company: ARISAN THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …ance mechanisms to inhibit both amantadine-sensitive and -resistant forms of the M2 proton channel. Optimization of these chemical series could provide novel broad-spectrum therapeutics for new mono- and combination antiviral drug therapies for influenza A; a designated NIAID… more
Company: AURITEC PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … action, and the prevention of resistance. The rationale for the choice of the drugs is very strong as theseare currently the only drugs to have demonstrated efficacy in clinical studies of HIV transmission. Funded in part by R21, R33, and SBIR grants from the NIAID, we have… more
Company: GENVEC, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …, andwith positive results, advance to human clinical testing. Our probability of success is increased by our experience with key RSV animal models, adenoviral vector vaccines, and our collaboration with a leader in the field of RSV research, Barney Graham, VRC, NIAID. The… more
Company: GLSYNTHESIS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … and guinea pig models, respectively, will be conducted by subcontractor Dr. James M. Hill at LSU Health Sciences Center, New Orleans, and by Drs. David Bernstein and Rhonda Cardin of Cincinnati Children's Hospital Medical Center, under contract from NIAID (Dr.… more
Company: HAWAII BIOTECH, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … Emerging and reemerging infectious diseases continue to pose serious health threats world-wide. Consequently, the development of measures to mitigate the natural, as well as potential bioterrorist threats of these infectious diseases is an important endeavor. The NIAID… more
Company: IMMPORT THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …. By synergistically incorporating novel ALCAT-based approaches into these arrays we will have the versatility and power to reduce enzymatic development times, limit production costs, and fully integrate all components into a disposable assay. From previous NIH/NIAID funding we… more
Company: Investigen, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …. Accordingly, the project is relevant to the NIH mission of reducing the burden of illness through supporting research for the improved diagnosis, prevention and cure of human diseases. The development of technologies for the easy/rapid detection of MDR/XDR-TB is a NIAID… more
Company: Lynntech, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … A, B, E, and F are known to be pathogenic in humans. Owing to their high toxicity and to the ease of their production and potential dissemination into air, water, and food supply, the BoNTs are considered among the preeminent bioterrorism threats. As such, the NIAID and CDC… more
Company: MOLECULAR TARGETING TECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / STTR / 2012 / 2
Abstract: DESCRIPTION (provided by applicant): According to the NIAID fact sheet on Botulism, the extreme toxicity of botulinum neurotoxins (BoNT) and the ease of production, transport, and delivery make this an agent of extreme bioterrorism concern. Nonetheless, although there are… more
Company: NORWELL, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: …s to complete preclinical studies of a trivalent adenoviral vaccine against plague in preparation for human clinical trials. The plague vaccine project was selected in responseto the growing concern surrounding the organism's possible use in a terrorism event. The NIAID and… more
Company: PROFECTUS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … rhFLSC provided significant protection against rectal challenge with multiple, low doses of R5 tropic, and heterologous SHIV162P3. These observations propelled FLSC into preclinical development and evaluation in a phase 1 clinical trial (supported by BMGF, MHRP, NIAID).… more
Company: SANARIA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: … protection in mice, and 4) our colleagues in the Netherlands' report that PfSPZ infection of volunteers taking chloroquine induced 100% protection that lasted for at least 28 months. Trials of PfSPZ Vaccine administered intravenously (IV) are now planned for the NIAID… more
Company: SANARIA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … NIH Chemical Genomics Center (NCGC) use the methods developed in Specific Aims 1 and 2 to screen a 2,500 compound library to identify target compounds with activity against liver stage parasites, including hypnozoites. 4) In collaboration with the Wellems group at NIAID/NIH… more
Company: TECHLAB, INC. Agency/Program/Year/Phase: HHS / STTR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): The NIAID Category B priority pathogen Entamoeba histolytica is a public health threat, especially as a cause of diarrhea in travelers to and immigrants from endemic areas, men who have sex with men, and children in thedeveloping world where… more
Company: GENEFLUIDICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: … choice. Not surprisingly, quinolone-resistant uropathogens are on the rise. In hospitals where MDR pathogens are of even greater problem, the quinolone-resistance rate foruropathogenic E. coli has now exceeded 50% in some settings. The goal of this Phase II NIAID Advanced… more
Company: RADIX THERAPEUTICS, LLC Agency/Program/Year/Phase: HHS / STTR / 2011 / 1
Abstract: … of this Phase I project is to explore an entirely new paradigm for preventing seasonal AR, employing an antibody-based, nasal prophylactic to be used only when patients know they will be exposed to large quantities of specific allergens. This project builds upon our… more
Company: BIOHELIX CORPORATION Agency/Program/Year/Phase: HHS / STTR / 2011 / 1
Abstract: DESCRIPTION (provided by applicant): This STTR-AT-NIAID seeks to develop an integrated nucleic acid system based on research done by Catherine Klapperich's laboratory at Boston University. The BU lab-on-a-chip includes a micro solid phase extraction (lt SPE) column, flap… more
Company: Caldera Pharmaceuticals, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: …e Strategic National Stockpile (SNS). This project is guided by the Guidance for Industry: Internal Radioactive Contamination -Development of Decorporation Agents. Sr-90 is easily obtained by terrorists;radioactive Sr-decorporation is a very high DHHS / NIH / NIAID / DAIT… more
Company: Guild Associates, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: DESCRIPTION (provided by applicant): Yersinia pestis is designated by the Centers for Disease Control (CDC) and NIAID as a Category A bacterial pathogen. Y. pestis is the etiological agent of the plague (Black Death), a transmissible disease that has beenresponsible for millions… more
Displaying 1 – 25 of 147 Awards
Narrow Your Search
By Year
By Phase
By Program
By State
By Company Ownership
By Company
HELP FOR NARROW YOUR SEARCH

Search Options

There are several categories such as “By Agency”, “By Year”, “By State” etc. Select a checkbox within a category to refine your search results.

Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.


Search for Either Criteria

When you select multiple values within a category, the results will include values that match either of the selections. For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.


Narrowing the Search Results

You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories. For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.